Actively Recruiting
A Study of GC203 TIL in Advanced Malignant Solid Tumors
Led by Shanghai Juncell Therapeutics · Updated on 2025-12-11
18
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
CONDITIONS
Official Title
A Study of GC203 TIL in Advanced Malignant Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to sign informed consent and complete all study procedures
- Between 18 and 75 years old at time of consent
- Have advanced metastatic solid tumors with clear pathological diagnosis and failed standard therapies
- Have feasible tissue for tumor resection/puncture to generate GC203 TIL with tissue volume > 400mm3
- Have at least one measurable target lesion before preconditioning as per RECIST 1.1
- Have ECOG performance status of 0 or 1
- Have estimated life expectancy of at least 3 months
- Meet specified hematologic, coagulation, hepatic, and renal function parameters
- Women of child-bearing potential must have a negative pregnancy test and agree to use effective birth control
- No contraindications for surgery or biopsy
- Able to comply with study requirements and visits
You will not qualify if you...
- Participated in clinical trials of other drugs or biologics within 4 weeks before enrollment
- History of allogeneic T cell therapy or gene-engineered autologous cell therapy within 1 year
- Received systemic antitumor therapy within 4 weeks
- Had another primary malignancy within the previous 5 years
- Received live or attenuated vaccination within 28 days prior to treatment
- History of hypersensitivity to any study drug components
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, China, 200032
Actively Recruiting
Research Team
H
Huajun Jin, PhD
CONTACT
X
Xiaohua Wu, Phd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here